A5067671033- Dermatology and Skin Diseases
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Psoriasis: Treatment and Pathogenesis
- Urticaria and Related Conditions
- Autoimmune Bullous Skin Diseases
- Food Allergy and Anaphylaxis Research
- Contact Dermatitis and Allergies
- Health Systems, Economic Evaluations, Quality of Life
- Autoimmune and Inflammatory Disorders
- Drug-Induced Adverse Reactions
- Hidradenitis Suppurativa and Treatments
- Olfactory and Sensory Function Studies
- Colorectal and Anal Carcinomas
- Nail Diseases and Treatments
- Pharmacological Effects of Natural Compounds
- Dermatological and COVID-19 studies
- Hedgehog Signaling Pathway Studies
- Plant Surface Properties and Treatments
- COVID-19 and healthcare impacts
- Data-Driven Disease Surveillance
- Infection Control and Ventilation
- Protein Degradation and Inhibitors
- Mast cells and histamine
- Climate Change and Health Impacts
Ospedale San Bortolo
2017-2025
Centro Studi GISED
2017-2024
Presidio Ospedaliero
2023
Ospedale Maggiore
2023
Erasmus MC
2018-2021
Erasmus University Rotterdam
2020-2021
University of Verona
2014-2019
Generalized pustular psoriasis (GPP) is a rare, severe inflammatory skin disease characterized by recurrent episodes of flares. Characteristics patients experiencing flare are hardly described in real-life setting. The aim the study to investigate clinical characteristics GPP.Multicenter retrospective observational on consecutive GPP between 2018 and 2022. Disease severity quality life were assessed Pustular Psoriasis Area, Body Surface Area (BSA), Severity Index (GPPASI), Dermatology index...
Background: Limited real-world data are available on upadacitinib drug survival in patients with atopic dermatitis (AD). Objectives: To investigate survival, and the reasons predictors of discontinuation AD patients. Methods: All consecutive aged 18–75 years, affected by moderate-to-severe AD, treated for more than 1 month at dermatological clinics were included during November 2020–August 2023. Upadacitinib was investigated through Kaplan–Meier analysis multivariable logistic regression...
Additional data supporting the findings of this manuscript are available on reasonable request to corresponding author.
Background: Dupilumab has been shown to be a safe and effective drug for the treatment of atopic dermatitis (AD) in children from 6 months 11 years randomized clinical trials. Aim: The aim this real-life study was determine effectiveness disease control safety dupilumab at W52 moderate-to-severe AD aged 6-11 years.Methods: All data were collected 36 Italian dermatological or paediatric referral centres. administered label dosage with an induction dose 300 mg on day 1 (D1), followed by D15...
Abstract Background Tralokinumab has demonstrated efficacy in the treatment atopic dermatitis (AD) both clinical trials and real-world settings. However, limited data exists on long-term use of tralokinumab Objective A multicentric Italian study, evaluating tralokinumab's drug survival (DS) up to 18 months among 471 patients with severe AD was conducted. Methods EASI (Eczema Area Severity Index), P-NRS (Pruritus Numerical Rating Scale), SD-NRS (Sleep Disturbance NRS), DLQI (Dermatology Life...
Atopic dermatitis (AD) is a chronic inflammatory skin condition that significantly impairs the quality of life. Recent advancements in systemic therapies, such as Janus kinase (JAK) inhibitors, offer very effective new treatment options. However, concerns regarding potential adverse events, including cardiovascular and thromboembolic risk, have emerged from clinical studies call for further real-life investigations. This has highlighted need to establish specific risk categories, tobacco...
Background/Objectives: Tralokinumab, a fully human monoclonal antibody targeting IL-13, has shown efficacy and safety in clinical trials real-life studies for atopic dermatitis (AD). However, data on its effectiveness across AD phenotypes are limited. Methods: A multicentric study evaluated tralokinumab’s over 52 weeks 416 severe patients. EASI (Eczema Area Severity Index), P-NRS (Pruritus Numerical Rating Scale), DLQI (Dermatology Life Quality ADCT (Atopic Dermatitis Control Tool) were...
Psoriasis, a chronic inflammatory skin disease, goes beyond visible symptoms and affects the general well-being of patients. The aim this study is to understand how patients with psoriasis perceive their characteristics reactivity allergens. population includes 11,283 participants within European Dermato-Epidemiology Network (EDEN) Fragrance study, covering several regions. compared perceptions dryness, sensitivity, product avoidance allergens between controls, evaluating potential influence...
Background Screening for latent tuberculosis infection (LTBI) is mandatory in patients with psoriasis prior to biological therapy. Objectives To investigate the prevalence of LTBI who are candidates Methods was investigated moderate-to-severe (n = 243), Crohn disease 64) or rheumatoid arthritis (RA) 56) and healthcare workers 1683). diagnosis based on positive QuantiFERON-B Gold In-Tube (QFT-GIT) vitro assay without any clinical, radiological microbiological evidence active tuberculosis....
Data on the psoriasis incidence and prevalence in Italian population are limited, a timely accurate understanding of disease epidemiology is needed. This ad hoc study investigated lifetime representative sample (n = 14,705) population. Information history skin disorders with details about their onset, duration, treatment was collected. Psoriasis showed bimodal distribution pattern, peaks age classes characteristic early-onset (35-44 years) late-onset (65-74 psoriasis. Late-onset some...